FDA approves drug that can delay onset of T1D
The FDA has now approved the use of teplizumab (Tzield), the world’s first ever immunotherapy for Type 1 diabetes, by people at risk of Type
The FDA has now approved the use of teplizumab (Tzield), the world’s first ever immunotherapy for Type 1 diabetes, by people at risk of Type